Who Owns Dermapharm Holding Company?

Dermapharm Holding Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Dermapharm Holding Company?

Understanding a company's ownership is key to grasping its direction and accountability. Dermapharm Holding SE's IPO in February 2018 marked a significant shift in its ownership structure.

Founded in 1991 by Wilhelm Beier, Dermapharm has grown into a major German pharmaceutical manufacturer. As of 2024, the company achieved consolidated revenue of EUR 1,180.8 million and adjusted EBITDA of EUR 315.6 million.

Initially, founder Wilhelm Beier held a significant stake. Following the 2018 IPO, ownership diversified to include public shareholders. Key investors and institutional holders also play a role in shaping the company's strategic path, influencing its growth and market presence, including its Dermapharm Holding Porter's Five Forces Analysis.

Dermapharm Holding SE was established in 1991 by Wilhelm Beier, who had already begun his career in the pharmaceutical sector in 1981. Beier initially served as the Chief Executive Officer before moving to the role of Chairman of the Supervisory Board in 2017. While specific details about the initial equity distribution or early investors are not publicly disclosed, it is confirmed that Wilhelm Beier and his family have maintained a controlling interest in the company through Themis Beteiligungs AG.

Founding Vision

Wilhelm Beier founded Dermapharm Holding SE in 1991, bringing extensive experience from his career in the pharmaceutical industry. His leadership has been instrumental in shaping the company's direction since its inception.

Leadership Transition

Beier transitioned from his role as CEO to Chairman of the Supervisory Board in 2017. This move signifies a strategic shift in his involvement while maintaining oversight of the company's governance.

Family Control

The Beier family, through Themis Beteiligungs AG, has consistently held a majority stake in Dermapharm Holding SE. This enduring family ownership underscores a commitment to long-term strategic control and stability.

Ownership Structure

While early investment details are not public, the family's significant and continuous majority ownership suggests a consolidated control structure from the company's early stages. This has likely influenced strategic decisions and company development.

Early Agreements

Public records do not detail specific early agreements like vesting schedules or buy-sell clauses. However, the sustained majority ownership by the founder's family implies a robust and stable ownership framework.

Founder's Legacy

Wilhelm Beier's foundational role and continued influence through family ownership highlight a deep-rooted connection to the company's origins. This structure supports a consistent vision for Dermapharm Holding SE's future growth and operations.

The consistent majority ownership by Wilhelm Beier and his family through Themis Beteiligungs AG indicates a strong, consolidated control structure from the company's inception. This family-centric approach has likely fostered a stable environment for strategic planning and execution, contributing to the company's sustained development. Understanding this foundational ownership is key to grasping the company's trajectory and its Revenue Streams & Business Model of Dermapharm Holding.

Key Ownership Aspects

The ownership of Dermapharm Holding SE is significantly influenced by its founder, Wilhelm Beier, and his family. Their sustained majority stake through Themis Beteiligungs AG is a defining characteristic of the company's governance and strategic direction.

• Founded in 1991 by Wilhelm Beier.
• Wilhelm Beier transitioned to Chairman of the Supervisory Board in 2017.
• The Beier family maintains a majority stake via Themis Beteiligungs AG.
• This structure suggests a long-term vision and consolidated control.

Dermapharm Holding SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Dermapharm Holding SE saw a significant shift with its Initial Public Offering (IPO) on February 9, 2018. This event on the Frankfurt Stock Exchange established a new phase for the company's shareholder base.

Following its public debut, the Beier family, through Themis Beteiligungs-Aktiengesellschaft, has maintained a dominant position as the majority shareholder. This enduring control highlights their significant influence on the company's strategic direction and overall governance. The company's financial performance in 2024, with consolidated revenue reaching EUR 1,180.8 million and adjusted EBITDA at EUR 315.6 million, underscores the stability and strength of its operational framework under this ownership structure.

Key Stakeholders in Dermapharm Holding SE

Understanding who owns Dermapharm Holding SE is crucial for assessing its strategic direction. The Beier family remains the controlling interest, supported by institutional investors.

• Wilhelm Beier is the largest shareholder, holding 77.08% of the equities as of July 2025.
• The Beier family's stake is primarily held through Themis Beteiligungs-Aktiengesellschaft.
• Mawer Investment Management Ltd. is a notable institutional investor, owning 2.971% of the shares.
• The company's ownership history shows a clear continuation of founder family control post-IPO.
• Dermapharm Holding is a publicly traded company, with its ownership structure readily available through mandatory publications, offering transparency for investors interested in its Marketing Strategy of Dermapharm Holding.

Dermapharm Holding PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Dermapharm Holding SE operates with a two-tier board structure, featuring a Management Board and a Supervisory Board. As of July 2025, the Management Board is led by Dr. Hans-Georg Feldmeier as CEO, with Christof Dreibholz serving as CFO and Dr. Andreas Eberhorn as CMO. The Supervisory Board is chaired by the company's founder, Wilhelm Beier.

The Supervisory Board, responsible for overseeing the Management Board, is chaired by Wilhelm Beier, the company's founder. The average tenure of the board members is approximately 7.9 years, reflecting a seasoned group of directors. Wilhelm Beier's leadership of the Supervisory Board, combined with his family's majority shareholding via Themis Beteiligungs AG, grants them substantial influence and control over the company's strategic direction. The voting structure adheres to a one-share-one-vote principle, with the Beier family's significant stake ensuring their considerable voting power. At the financial year 2024 Annual General Meeting on June 26, 2025, 14.6% of the share capital was represented, with shareholders overwhelmingly approving management proposals, including the ratification of the Management Board's actions with a 99.2% majority and the Supervisory Board's actions with an 89.4% majority.

Understanding Dermapharm Holding's Ownership Structure

The ownership of Dermapharm Holding SE is largely concentrated, with the founder's family holding a majority stake. This structure significantly influences the company's decision-making processes.

• The Beier family, through Themis Beteiligungs AG, is the majority shareholder.
• Wilhelm Beier, the founder, chairs the Supervisory Board.
• The company follows a one-share-one-vote system.
• The latest AGM saw strong shareholder support for board actions.
• Understanding this ownership is key to grasping Dermapharm Holding's strategic direction.

Dermapharm Holding Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the last few years, Dermapharm Holding SE has been actively pursuing a growth strategy that includes strategic acquisitions and expanding its international presence. These moves are shaping its ownership trends and market position.

Dermapharm Holding SE reported strong financial results for the fiscal year 2024, with consolidated revenue reaching EUR 1,180.8 million and adjusted EBITDA at EUR 315.6 million. Looking ahead to 2025, the company anticipates consolidated revenue to be between EUR 1,160 million and EUR 1,200 million, with adjusted EBITDA projected to increase to EUR 322 million to EUR 332 million. Recent insider transactions, including purchases by Wilhelm Beier and Themis Beteiligungs-Aktiengesellschaft in late 2024 and early 2025, and by Dr. Hans-Georg Feldmeier and Dr. Andreas Eberhorn in June 2025, indicate sustained confidence from key individuals and entities in the company's future performance. This consistent focus on R&D and external growth opportunities suggests that strategic acquisitions may continue to influence Dermapharm Holding SE's ownership structure.

Strategic Acquisitions Drive Growth

Dermapharm's acquisition of Allergopharma in 2020 and the C³ Group in 2022 highlights a strategy to broaden its product portfolio and market reach. These moves are key to its ongoing expansion.

Insider Confidence and Financial Outlook

Recent share purchases by management and key stakeholders, coupled with positive financial projections for 2024 and 2025, signal strong internal belief in the company's trajectory. This trend is important for understanding Dermapharm Holding ownership.

Future Ownership Trends

The company's commitment to both organic growth and strategic acquisitions suggests that its ownership structure may evolve further. This could involve capital increases or other share-based transactions as it pursues new opportunities.

Market Position and Expansion

Dermapharm's strategic expansion efforts are aimed at strengthening its market position. Understanding the Competitors Landscape of Dermapharm Holding provides context for these strategic decisions and their impact on ownership.

Dermapharm Holding Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔